|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We recently reported that the vast majority (>90%) of low-grade diffuse gliomas (diffuse astrocytoma, oligoastrocytoma and oligodendroglioma) carry at least one of the following genetic alterations: IDH1/2 mutation, TP53 mutation or 1p/19q loss.
|
21470325 |
2011 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified mutations that affected amino acid 132 of IDH1 in more than 70% of WHO grade II and III astrocytomas and oligodendrogliomas and in glioblastomas that developed from these lower-grade lesions.
|
19228619 |
2009 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We hypothesize that the mutant CIC on the single retained 19q allele is linked to the pathogenesis of oligodendrogliomas with IDH mutation.
|
22072542 |
2012 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that NHE-1 on 1p is silenced in oligodendrogliomas secondary to IDH-associated hypermethylation and 1p allelic loss.
|
22718548 |
2012 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found 165 IDH1 (72.7%) and 2 IDH2 mutations (0.9%) in 227 diffuse astrocytomas WHO grade II, 146 IDH1 (64.0%) and 2 IDH2 mutations (0.9%) in 228 anaplastic astrocytomas WHO grade III, 105 IDH1 (82.0%) and 6 IDH2 mutations (4.7%) in 128 oligodendrogliomas WHO grade II, 121 IDH1 (69.5%) and 9 IDH2 mutations (5.2%) in 174 anaplastic oligodendrogliomas WHO grade III, 62 IDH1 (81.6%) and 1 IDH2 mutations (1.3%) in 76 oligoastrocytomas WHO grade II and 117 IDH1 (66.1%) and 11 IDH2 mutations (6.2%) in 177 anaplastic oligoastrocytomas WHO grade III.
|
19554337 |
2009 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We excluded glioblastoma-like tumors (7a10d subgroup) and derived a gene expression signature distinguishing histologically classified oligodendrogliomas with concurrent 1p/19q co-deletion and IDH mutation (1p/19q subgroup) from those with predominant IDH mutation alone (IDHme subgroup).
|
29631562 |
2018 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We evaluated nuclear cMYC protein levels and IDH1 (R132H) by immunohistochemistry in patients with oligodendroglioma/oligoastrocytomas (n = 20), astrocytomas (grade II) (n = 19), anaplastic astrocytomas (n = 21) or glioblastomas (n = 111).
|
23934175 |
2013 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We analyzed markers, including IDH mutation(IDHmut), 1p19q codeletion(1p19qcodel), ATRX expression loss(ATRX loss) and p53 overexpression, and outcomes in 159 patients with WHO grade II oligodendroglioma, oligoastrocytoma, and astrocytoma (2003-2012).
|
26210286 |
2015 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Trisomy of chromosome 7 in IDH mutated astrocytoma and PTEN mutations in IDH mutated oligodendroglioma are potential markers of poor prognosis, but require confirmation in larger series.
|
29663171 |
2018 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Triple-positive (IDH1 and TERT mutation with 1p19q codeletion) glioma tended to be oligodendroglioma present with much better clinical outcome compared to TERT mutation only group who is glioblastoma inclined (median overall survival 39 months VS 18 months).
|
28915860 |
2017 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To investigate the relationship between 3 hypoxic markers, carbonic anhydrase-9 (CA-9), hypoxia-inducible factor (HIF)-1α, and HIF-2α and the traditional genetic markers, deletions of chromosomes 1p and 19q and Isocitrate dehydrogenase 1 (IDH1) R132H mutation in oligodendrogliomas.
|
26960282 |
2016 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Three GBM-O samples had IDH1 (p.R132H) mutations; two of these also demonstrated 1p/19q co-deletion and had a proneural transcriptional profile, a molecular signature characteristic of oligodendroglioma.
|
26757882 |
2016 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Those tumors that lacked LOH 1p19q showed a high frequency of IDH1 mutations and loss of alpha thalassemia/mental retardation syndrome X-linked gene (ATRX) immunoreactivity, indicating a possible phenotypic convergence of true oligodendrogliomas and gliomas of the alternative lengthening of telomeres (ALT) pathway. p53 alterations were common irrespective of the 1p19q status.
|
24444336 |
2014 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The reported two cases were initially diagnosed as oligodendroglioma with 1p/19q-codeletion and mutation of <i>isocitrate dehydrogenase 1 (IDH1)</i>-R132H.
|
31508376 |
2019 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The relationship between chromosome 1p and 19q deletions and treatment responsive oligodendrogliomas is discussed, as are the newer advances relating to silencing of the MGMT gene in astrocytomas and mutations in the IDH-1 gene in both astrocytomas and oligodendrogliomas.
|
21233669 |
2011 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The NGS approach was effective in reclassifying 36 oligoastrocytomas as 30 astrocytomas (20 IDH1/2 mutant and 10 IDH1/2 wild type) and 6 oligodendrogliomas, and 1 oligodendroglioma as an astrocytoma (IDH1/2 mutant).
|
28042970 |
2017 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The mutation analysis performed on the latter case with DNA separately sampled from the oligodendroglioma- like area and the astrocytoma-like area detected IDH1 G395A in both areas.
|
22385787 |
2012 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The meeting consisted of 3 scientific sessions ranging from neuropathology of IDH1 mutations; CIC, ATRX, and FUBP1 mutations in oligodendrogliomas and astrocytomas; and IDH1 mutations as therapeutic targets.
|
23373454 |
2013 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The majority of oligodendrogliomas (ODGs) exhibit combined losses of chromosomes 1p and 19q and mutations of isocitrate dehydrogenase (IDH1-R132H or IDH2-R172K).
|
25277207 |
2014 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The first of these enzymes is isocitrate dehydrogenase 1 (IDH1), which is mutated in secondary glioblastomas and ~70% of grade II/III astrocytomas and oligodendrogliomas.
|
23432648 |
2013 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The EMP3 and MGMT promoter methylation was more frequent in OII than in GBM patients, and the IDH1 mutation was absent in GBM.
|
22992787 |
2012 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The DSC-MRI procedure may provide insight into the IDH1/2 mutation and ATRX expression status and MGMT methylation profile of diffuse glioma; however, taking integrated oligodendroglioma into account limits the diagnostic performance of rCBV in non-invasively predicting the molecular subtype.
|
29468261 |
2019 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The oligodendroglioma model presented here is a valuable model for further functional elucidation of the effects of IDH1 mutations on tumor metabolism and may aid in the rational development of novel therapeutic strategies for the large subgroup of gliomas carrying IDH1 mutations.
|
24252742 |
2013 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The 25th, 50th, 75th, and 90th percentiles of MK and average MK showed significant differences between IDH1/2<sub>wild-type</sub> gliomas, IDH1/2<sub>mutated</sub> gliomas, and oligodendrogliomas with chromosome 1p/19q loss of heterozygosity and IDH1/2<sub>mutation</sub> (p<0.001).
|
28987669 |
2017 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Sixty-five patients with 2007 histological designations (astrocytomas and oligodendrogliomas), 1p/19q status (+ = intact/- = co-deleted), and IDH1 mutation status (MUT/WT) were included in this study.
|
28547590 |
2017 |